Upsurge in consumption in low and middle-income countries (LMICs), increase in prevalence of infectious diseases, and adoption of novel approaches for treatment of bacterial infections drive the ...

Please provide your email address to receive an email when new articles are posted on . A metallo-beta-lactam inhibitor could help fight resistance to beta-lactam antibiotics. MK-3402 was found to be ...

WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...

SAN DIEGO--(BUSINESS WIRE)--Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several ...

Pfizer has just completed phase 3 trials of a new antibiotic that's active against highly resistant Gram-negative infections. It's a real superbug fighter. But what took so long? Once upon a time in a ...

Shionogi manufactures and markets cefiderocol, a beta-lactam antibiotic that utilizes a clever siderophore strategy to enter and kill multi-resistant Gram-negative pathogens. Shionogi just entered a ...

Houston, TX – New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial ...

Paris, France, 22 January 2008 -- Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has entered into an ...

MONTREAL, QUEBEC -- MethylGene Inc. announced that it has received notice today that Merck intends to terminate the exclusive license and research collaboration agreement, entered into by the ...

Please provide your email address to receive an email when new articles are posted on . Gram-negative bacteria comprise most of the CDC and WHO’s lists of critical and urgent antibiotic-resistant ...